The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-28), Cocrystal Pharma's share price is $1.555. Cocrystal Pharma's Book Value per Share for the quarter that ended in Dec. 2023 was $2.59. Hence, Cocrystal Pharma's PB Ratio of today is 0.60.
The historical rank and industry rank for Cocrystal Pharma's PB Ratio or its related term are showing as below:
COCP'
s PB Ratio Range Over the Past 10 Years
Min: 0.14 Med: 1.01 Max: 18.79
Current: 0.6
During the past 13 years, Cocrystal Pharma's highest PB Ratio was 18.79. The lowest was 0.14. And the median was 1.01.
COCP's PB Ratio is ranked better than 89.3% of 1309
companies
in the Biotechnology industry
Industry Median: 2.38
vs COCP: 0.60
During the past 12 months, Cocrystal Pharma's average Book Value Per Share Growth Rate was -46.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -33.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -31.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cocrystal Pharma was 38.70% per year. The lowest was -70.60% per year. And the median was -33.10% per year.
Back to Basics: PB Ratio
Cocrystal Pharma PB Ratio Historical Data
The historical data trend for Cocrystal Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cocrystal Pharma's PB Ratio
For the Biotechnology subindustry, Cocrystal Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's PB Ratio falls into.
Cocrystal Pharma PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cocrystal Pharma PB Ratio Related Terms
Thank you for viewing the detailed overview of Cocrystal Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Cocrystal Pharma (Cocrystal Pharma) Business Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COCP has been successfully added to your 